News

In Cushing’s disease (CD), depression is correlated with body image distortion and lower self-esteem, according to an Indian study. Physicians should be attentive to symptoms of mental disturbances in CD patients to provide them a better prognosis. The research, “A Study on Psychiatric Disorders, Body Image…

Medical therapy using cabergoline is an option for treating patients with persistent or recurrent Cushing’s disease after transsphenoidal surgery, new research from India shows. The study, “Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta‑analysis,” was published in the Journal of Endocrinological Investigation. Cushing’s disease is most…

Minimally invasive diagnostic methods and transnasal surgery may lead to remission in nearly all children with Cushing’s disease, while avoiding more aggressive approaches such as radiation or  removal of the adrenal glands, a study shows. The study, “A personal series of 100 children operated for Cushing’s…

OvaScience and Millendo Therapeutics will merge in an all-stock deal to push forward Millendo’s lead candidates livoletide (AZP-531) and nevanimibe (ATR-101) for the treatment of Prader-Willi syndrome and Cushing’s syndrome, respectively. An investor group that includes New Enterprise Associates, Frazier Healthcare Partners, Roche…

Recorlev (levoketoconazole) safely and successfully reduces the levels of cortisol in patients with endogenous Cushing’s syndrome, according to top-line results of a Phase 3 clinical trial. Cushing’s syndrome occurs due to abnormally high levels of cortisol, mainly caused by prolonged exposure to cortisol-like steroid medications and less commonly by…

A test using betamethasone — a corticosteroid that causes the pituitary gland to stop producing ACTH – can accurately predict short- and long-term remission in Cushing’s disease patients who have had pituitary surgery, a retrospective study reports. The research, “An early post-operative ACTH suppression test can safely predict short- and long-term…

Korlym (mifepristone) is effective for the treatment of ectopic Cushing’s syndrome patients, with survival rates comparable to patients who undergo bilateral adrenalectomy (removal of the adrenal glands), new research shows. The study, “Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome,” was published in the journal…

American and Dutch patients with Cushing’s syndrome have different ways of interpreting the same items on a disease-specific quality-of-life (QoL) questionnaire, research shows. The study, “Assessing Differences in How the CushingQoL Is Interpreted Across Countries: Comparing Patients From the U.S. and the Netherlands,” was published in…